Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: Results from a randomized study in patients with migraine

Cephalalgia

Volumn 33, Issue 16, 2013, Pages 1292-1301

  Depre M ^a   Macleod, C ^b   Palcza, J ^b   Behm, M O ^b   De Lepeleire, I ^c   Han, T ^b   Panebianco, D ^b   Smith, W B ^d   Blanchard, R ^b   Chodakewitz, J A ^b   Murphy, M G ^b   De Hoon, J N ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MSD Europe Inc   (Belgium)

^d UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

blood pressure; CGRP receptor antagonist; migraine; sumatriptan; telcagepant; Triptan

Indexed keywords

SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TELCAGEPANT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HEADACHE; HEMODYNAMICS; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; MIGRAINE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

BLOOD PRESSURE; CGRP RECEPTOR ANTAGONIST; MIGRAINE; SUMATRIPTAN; TELCAGEPANT; TRIPTAN;

ADULT; ANALGESICS; AZEPINES; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEMODYNAMICS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SUMATRIPTAN; YOUNG ADULT;

EID: 84887847827     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102413494272     Document Type: Article

References (34)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med. 2002 ; 346: 257-270 (Pubitemid 34438866)
2. Tfelt-Hansen P, de Vries P, Saxena P. Triptans in migraine. Drugs. 2000 ; 60: 1259-1287
3. Dodick D, Lipton RB, Martin V, et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004 ; 44: 414-425 (Pubitemid 38685549)
4. Edvinsson L, Uddman E, Wackenfors A, et al. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: Relationship to clinical effect. Clin Sci. 2005 ; 109: 335-342 (Pubitemid 41337139)
5. Ho T, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nature Rev Neurol. 2010 ; 6: 573-582
6. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation during migraine headache. Ann Neurol. 1990 ; 28: 183-187 (Pubitemid 20244522)
7. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993 ; 33: 48-56 (Pubitemid 23009909)
8. Lassen LH, Jacobsen VB, Petersen P, et al. Human calcitonin gene-related peptide (hCGRP)-induced headache in migraineurs. Eur J Neurol. 1998 ; 5: S63 - S63
9. van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997 ; 21: 649-678 (Pubitemid 27458805)
10. Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: A new target in the treatment of headache. Cephalalgia. 2004 ; 24: 611-622 (Pubitemid 39061250)
11. Rudolf K, Eberlein W, Engel W, et al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)- oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl) piperazine: The first CGRP antagonist for clinical trials in acute migraine. J Med Chem. 2005 ; 48: 5921-5931 (Pubitemid 41324603)
12. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004 ; 350: 1104-1110 (Pubitemid 38298990)
13. Paone DV, Shaw AW, Nguyen DN, et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: Discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2- trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-yl) piperidine-1-carboxamide (MK-0974). J Med Chem. 2007 ; 50: 5564-5567 (Pubitemid 350106011)
14. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomized, placebo-controlled, parallel-treatment trial. Lancet. 2008 ; 372: 2115-2123
15. Tepper SJ, Stillman MJ. Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. Headache. 2008 ; 48: 1259-1268
16. Petersen KA, Birk S, Lassen LH, et al. The CGRP antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005 ; 25: 139-147 (Pubitemid 40193957)
17. The International Classification of Headache Disorders: 2nd ed. Cephalalgia. 2004 ; 24: 9-160
18. Sternieri E, Pinetti D, Coccia C, et al. Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients. J Headache Pain. 2005 ; 6: 319-321 (Pubitemid 41349338)
19. Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: Telcagepant and topiramate. Lancet. 2010 ; 376: 645-655
20. Chan KY, Vermeersch S, de Hoon J, et al. Potential mechanism of prospective antimigraine drugs: A focus on vascular (side) effects. Clin Pharmacol Ther. 2011 ; 129: 332-351
21. Cady R, Schreiber C. Sumatriptan: Update and review. Expert Opin Pharmacother. 2006 ; 7: 1503-1514 (Pubitemid 44173211)
22. de Hoon JN, Willigers JM, Troost J, et al. Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther. 2000 ; 68: 418-426
23. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008 ; 70: 1304-1312 (Pubitemid 351550355)
24. Sinclair SR, Kane SA, Van der Schueren BJ, et al. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br J Clin Pharmacol. 2010 ; 69: 15-22
25. Swan L, Hood S, Birnie DH, et al. The haemodynamic effect of the 5HT1 agonist BMS-180048: A class effect of triptans?. Br J Clin Pharmacol. 1999 ; 47: 189-194 (Pubitemid 29078018)
26. Vanmolkot F, de Hoon JN. Acute effects of sumatriptan on aortic blood pressure, stiffness and pressure waveform. Clin Pharmacol Ther. 2006 ; 80: 85-94 (Pubitemid 43946843)
27. Goldberg MR, Lee Y, Vyas KP, et al. Rizatriptan, a novel 5-HT1B/1D agonist for migraine: Single- and multiple-dose tolerability and pharmacokinetics in healthy subjects. J Clin Pharmacol. 2000 ; 40: 74-83
28. Peck RW, Seaber EJ, Dixon RM, et al. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitritan in healthy young and elderly men and women. Clin Pharmacol Ther. 1998 ; 63: 342-353 (Pubitemid 28182232)
29. Vanmolkot FH, de Hoon JN, Barrington P, et al. Non-invasive assessment of selective 5-HT(1B/1D)-receptor agonist-induced peripheral vascular effects in humans: Comparison of different techniques. Eur J Clin Pharmacol. 2002 ; 58: 303-308 (Pubitemid 34983919)
30. Vanmolkot FH, Van Bortel LM, de Hoon JN. Altered arterial function in migraine of recent onset. Neurology. 2007 ; 68: 1563-1570 (Pubitemid 46717979)
31. Blanchard RL, Rowe J, Palcza J, et al. High dose telcagepant has no effect on 24-hr ambulatory blood pressure or heart rate in healthy volunteers. Headache. 2010 ; 50: S35 - S35
32. Van der Schueren BJ, Blanchard R, Murphy MG, et al. The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol. 2011 ; 71: 708-717
33. Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol. 1994 ; 47: 1253-1257 (Pubitemid 24127939)
34. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol. 1995 ; 47: 543-548